Facts, figures and trends in lead generation

Current Topics in Medicinal Chemistry

Volumn 4, Issue 6, 2004, Pages 569-580

  Deprez Poulain, Rebecca ^a   Deprez, Benoit ^a,b  

^a CNRS   (France)

^b UNIV LILLE   (France)

Author keywords

Druggability; Functional assay; High Throughput Screening (HTS); Hit to lead (H2L); Library design; Optimisation; Parallel synthesis; Rational drug design; Structure activity relationships (SAR); Structure property relationships (SPR)

Indexed keywords

4 CHROMANONE DERIVATIVE; AMIDE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; BENZODIAZEPINE; BENZOTHIAZEPINE DERIVATIVE; BIPHENYL DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 INHIBITOR; DIHYDROPYRIDINE DERIVATIVE; ENZYME INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; GROWTH HORMONE; HORMONE RECEPTOR; HYDROQUINONE DERIVATIVE; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; INSULIN; LIPOPEPTIDE; LIRAGLUTIDE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEW DRUG; PEPTIDE DERIVATIVE; PLASMEPSIN II; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG;

ACCURACY; BIOASSAY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG QUALITY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE POLARIZATION IMMUNOASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PLASMA PROTEIN BINDING; PROCESS OPTIMIZATION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG INDUSTRY; METHODOLOGY;

CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG INDUSTRY; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN;

EID: 2942685959     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451168     Document Type: Review

References (55)

1. Oprea, T.I.; Davis, A.M., Teague, S.J.; Leeson, P.D., Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
2. Fox, S.; Wang, H.; Sopchak, L.; Farr-Jones, S.; High throughput screening 2002, moving toward increased success rates. J. of Biomol. Screen. 2002, 7, 313-316.
3. Landro, J.A.; Taylor, I.C.A.; Stirtan, W.G.; Osterman, D.G.; Kristie, J.; Hunnicutt, E.J.; Rae, P.M.M., Sweetnam, P.M. HTS in the new millennium The role of pharmacology and flexibility. J. Pharmacol. Toxicol. Methods 2001, 44, 273-289.
4. MacLean, D.; Baldwin, J.J.; Ivanov, V.T.; Kato, Y.; Shaw, A.; Schneider, P.; Gordon, E.M. Glossary of terms used in combinatorial chemistry, J. Comb. Chem. 2000, 2, 562-578.
5. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings, PSTT 1998, 1, 387-393.
6. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 1997, 23, 3-25.
7. Oprea, T.I. Virtual Screening in Lead Discovery: A Viewpoint, Molecules 2002, 7, 51-62.
8. Veber, D.F.; Johnson, S.R.; Cheng, H-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D.; Molecular properties that influence the oral bioavailability of drugs candidates, J. Med. Chem. 2002, 45, 2615-2623.
9. Wermuth, C.-G.; Ganellin, C.R.; Lindberg, P.; Mitscher, L.A. Glossary of Terms used in Medicinal Chemistry (IUPAC Recommendations 1997). Ann. Rep. Med. Chem. 1998, 33, 385-395.
10. Proudfoot, J.R.; Drugs, Leads, and Drug-likeness: An Analysis of Some Recently launched Drugs. Bioorg, Med. Chem. Lett. 2002, 12, 1647-1650.
11. For a recent review on pharmacokinetics: Van de Waterbeemd, H.; Smith, D.A.; Beaumont, K.; Walker, D.K. Property-Based design: Optimization of Drug Absorption and Pharmacokinetics. J. Med. Chem. 2001, 44, 1313-1333.
12. Pickett, S.D.; McLay, I.M.; Clarck, D.E. Enhancing the Hit-to-Lead Properties of Lead Optimization Libraries. J. Chem. Inf. Comput. Sci. 2000, 40, 263-272.
13. Poulain, R.; Horvath, D.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.; Deprez, B. From Hit to Lead. Combining Two Complementary Methods for Focused Library Design. Application to μ opiate ligands. J. Med. Chem. 2001, 44, 3378-3390.
14. Stahura, F.L.; Xue, L.; Godden, J.W. ; Bajorath, J., Methods for compound selection focused on hits and application in drug discovery. J. Mol. Graph. Model. 2002, 20, 439-446.
15. Cavalli, A.; Recanatini, M. Looking for Selectivity among Cytochrome P450s Inhibitors. J. Med. Chem. (Letter) 2002, 45, 251-254.
16. Kumar, D.; Gupta, S.P. A Quantitative Structure-Activity relationship Study on Matrix Metalloproteinase and Collagenase Inhibitors. Bioorg. Med. Chem. 2003, 11, 421-426;
17. Poulain, R.; Horvath, D.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.; Deprez, B. From Hit to Lead. Analyzing Structure-Profile Relationships. Application to μ opiate ligands. J.Med.Chem. 2001, 44, 3391-3401.
18. Martin, Y.C.; Kofron, J.L.; Traphagen, L.M. Do Structurally Similar Molecules Have Similar Biological Activity? J.Med.Chem. 2002, 45, 4350-4358.
19. Lombardo, F.; Obach, R.S.; Shalaeva, M.Y.; Gao, F. Prediction of Volume of Distribution Values in Humans for Neutral and Basic Drugs Using Physicochemical Measurements and Plasma Protein Binding Data. J. Med.Chem. 2002, 45, 2867-2876.
20. Veber, D.F.; Johnson, S.R.; Cheng, H.-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J.Med.Chem. 2002, 45, 2615-2623.
21. Goodwin, J.T.; Conradi, R.A.; Ho, N.F.H.; Burton, P.S. Physicochemical Determinants of Passive Membrane Permeability: role of Solute Hydrogen-Bonding Potential and Volume. J. Med. Chem. 2001, 44, 3721-3729.
22. Sugano, K.; Hamada, H.; Machida, M.; Ushio, H. High Throughput Prediction of Oral Absorption: Improvement of the Composition of the Lipid Solution Used in Parallel Artificial Membrane Permeation Assay. J.Biomol.Screen. 2001, 6, 189-196.
23. Zamora, I.; Oprea, T.; Cruciani, G.; Pastor, M.; Ungell, A.-L. Surface Descriptors for Protein-Ligand Affinity Prediction. J.Med.Chem. 2003, 46, 25-33.
24. Hajduk, P.J.; Shuker, S.B.; Nettesheim, D.G.; Craig, R.; Augeri, D.J.; Betebenner, D.; Albert, D.H.; Guo, Y.; Meadows, R.P.; Xu, L.; Michaelides, M.; Davidsen, S.K.; Fesik, S.W. NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability. J.Med.Chem. 2002, 45, 5628-5639.
25. for an example of cyclic analogue of somatostatine see: Veber, D.F.; Saperstein, R.; Nutt, R.F.; Freidinger, R.M.; Brady, S.F.; Curley, P.; Perlow, D.S.; Paleveda, W.J.; Colton, C.D.; Zacchei, A.G.; Tocco, D.J.; Hoff, D.R.; Vandlen, R.L.; Gerich, J.E.; Hall, L.; Mandarino, L.; Cordes, E.H.; Anderson P.S.; Hirschmann, R. A super active cyclic hexapeptide analog of somatostatin. Life Sci. 1984, 34, 1371-1378)
26. Lubell, W.D. From Freidinger lactams toward a universal strategy for peptide mimicry. The importance of structural constraint for studying peptide function. 225th Meeting of the American Chemical Society, New Orleans 22-27 March 2003.
27. For an example of the use of lactams in a series of ORL receptor ligands: Halab, L.; Becker, J.A.J.; Darula, S.; Tourwe, D.; Kieffer, B.L.; Simonin, F.; Lubell, W.D. Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist. J. Med. Chem. 2002, 45, 5353-5357.
28. Sills, M.A.; Weiss, D.; Pham, Q.; Schweitzer, R.; Wu, X.; Wu, J.J. Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J.Biol.Screen. 2002, 7, 191-214.
29. Kenakin, T.; Onaran, O. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 2002, 23, 275-280.
30. Chalmers, D.T.; Behan, D.P. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat. Rev. Drug Discov. 2002, 1, 599-608.
31. Beeley, N.R. Can peptides be mimicked? Drug Discov. Today 2000, 5, 354-363.
32. Phillipson, D.W.; Milgram, K.E.; Yanovsky, A.I.; Rusnak, L.S.; Haggerty, D.A.; Farrell, W.P.; Greig, M.J.; Xiong, X.; Proefke, M.L. High-Throughput Bioassay-Guided Fractionation: A Technique for rapidly Assigning Observed Activity to Individual Components of Combinatorial Libraries, Screened in HTS Bioassays. J. Comb. Chem. 2002, 4, 591-599.
33. Teague, S.J; Davis, A.M.; Leeson, P.D.; Oprea, T. The Design of Leadlike Combinatorial Libraries. Angew.Chem.Int.ed. 1999, 38, 3743-3748.
34. McGovern, S.L.; Caselli, E.; Grigoriell, N.; Shoichet, B.K. A Common Mechanism Underlying Promiscuoous Inhibitors from Virtual and High-Throughput-Screening. J.Med.Chem. 2002, 45, 1712-1722.
35. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E.-M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Stjögren, E.; Fotouhi, N.; Gillepsie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; Von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries. J.Med.Chem. 2002, 45, 137-142.
36. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
37. For reviews on privileged structures see: (a) Patchett, A.; Nerdung, R. Privileged structures-An update. Annu.Rep.Med.Chem. 2000, 35, 289-298.
38. Horton, D.A.; Bourne, G.T.; Smythe, M.L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev. 2003, 103, 893-930.
39. Bemis, G.W.; Murcko, M.A. The Properties of Known Drugs. 1. Molecular Frameworks. J.Med.Chem. 1996, 39, 2887-2893.
40. Bemis, G.W.; Murcko, M.A. Properties of Known Drugs. 2. Side Chains. J.Med.Chem. 1999, 42, 5095-5099.
41. Hajduk, P.J.; Bures, M.; Praestgaards, J.; Fesik, S.W. Privileged Molecules for Protein Binding Identified from NMR-Based Screening. J.Med.Chem. 2000, 43, 3443-3447.
42. Lewell, X.Q.; Judd, D.B.; Watson, S.P.; Hann, M.M. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry. J. Chem. Inf. Comput. Sci. 1998, 38, 511-522.
43. Lee, M.-L.; Schneider, G. Scaffold Architecture and Pharmacophoric Properties of Natural Products and Trade Drugs: Application in the design of Natural Product-Based Combinatorial Libraries. J. Comb. Chem. 2001, 3, 284-289.
44. Wessjohann, L.A. Synthesis of natural-product-based compound libraries. Curr. Opin. Chem. Biol. 2000, 4, 303-309.
45. Tan, D.S.; Foley, M.A.; Shair, M.D.; Schreiber, S.L. Stereoselective Synthesis of over Two Milllion Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays. J. Am. Chem. Soc. 1998, 120, 8565-8566.
46. Spring, D.R.; Krishnan, S.; Schreiber, S.L. Towards Diversity-Oriented, Stereoselective Syntheses of Biaryl- or Bis(aryl)metal-Containing Medium Rings. J. Am. Chem. Soc. 2000, 122, 5656-5657.
47. Spring, D.R.; Krishnan, S.; Blackwell, H.E.; Schreiber, S.L. Diversity-Oriented Synthesis of Biaryl-Containing Medium rings Using a One Bead/One Stock solution Platform. J. Am. Chem. Soc. 2002, 124, 1354-1363.
48. Saunders, J. Screening the universal informer Library. CHI Meeting: Exploiting Molecular Diversity, Coronado, 2-4 March 1998.
49. Dolle, R.E. Comprehensive survey of Combinatorial Library Synthesis: 2000. J.Comb.Chem. 2001, 3, 1-41.
50. Haque, T.S.; Skillman, A.G.; Lee, C.E.; Habashita, H.; Gluzman, I.Y.; Ewing, T.J.A.; Goldberg, D.E.; Kuntz, I.D.; Ellman, J.A. Potent, low-molecular weight non-peptide inhibitors of malarial aspartylprotease plasmepsin II. J.Med.Chem. 1999, 42, 4380-4387.
51. Hann, M.M., Leach, A.R., Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
52. Van Dongen, M.J.P.; Uppenberg, J.; Svensson, S.; Lundbäck, T.; Åkerud, T.; Wikström, M.; Schultz, J. Structure-based Screening As Applied to Human FABP4: A Highly Efficient Alternative to HTS for Hit Generation. J. Am. Chem. Soc. 2002, 124, 11874-11880.
53. Dalvit, C.; Flocc, M.; Knapp, S.; Mostardini, M.; Perego, R.; Stockman, B.J.; Veronesi, M.; Varasi, M. High-Throughput NMR-Based Screening with Competition Binding Experiments. J. Am. Chem. Soc. 2002, 124, 7702-7709.
54. Liebeschuetz, J.W; Jones, S.D.; Morgan, P.J.; Murray, C.W.; Rimmer, A.D.; Roscoe, J.M.E.; Waszkowycz, B.; Welsh, P.M.; Wylie, W.A.; Young, S.C.; Martin, H.; Mahler, J.; Brady, L.; Wilkinson, K. PRO_SELECT: Combining Structure-Based Drug Design and Array-Based Chemistry for Rapid Lead Discovery. 2. The Development of a Series of highly Potent and Selective Factor Xa Inhibitors. J. Med. Chem. 2002, 45, 1221-1232.
55. Ramström, O.; Lehn, J.-M. Drug Discovery by Dynamic Combinatorial Libraries. Nat. Rev. Drug Disc. 2002, 1, 26-36.